<DOC>
	<DOCNO>NCT01436604</DOCNO>
	<brief_summary>The main objective study compare proportion late enhancement patient Left ventricular ( LV ) dysfunction Herceptin ® control group consist patient LV dysfunction 6 month treatment .</brief_summary>
	<brief_title>Early Detection Cardiac Toxicity Trastuzumab ( Herceptin ® ) Patients Treated Breast Carcinoma : Value Magnetic Resonance Imaging</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Women 18 year Free inform consent sign Histologically confirm adenocarcinoma breast , metastatic nonmetastatic LVEF &gt; 50 % angioscintigraphy start treatment Herceptin ® , Overexpression HER2 invasive component primary tumor ( 3 + 2 + accord ICH confirmation positivity FISH CISH ) Patient receive treatment Herceptin ® , Inclusion control group : patient treat Herceptin ® episode without LV dysfunction , For inclusion Group LV dysfunction : appearance decrease LVEF treatment Herceptin ® , angioscintigraphy identify . Heart disease serious medical condition allow administer Herceptin ® ( documented history heart failure , angina require treatment , severe dyspnoea rest oxygen dependency ) , History ischemic heart disease myocarditis Known allergy trastuzumab , murine protein excipients Patients indication MRI ( claustrophobia , ferromagnetic foreign body , pacemaker implantable defibrillator , know allergy gadolinium salt ) Renal impairment ( creatinine clearance &lt; 60 ml / min accord MDRD formula ) Arrhythmia atrial fibrillation , Contraindications administration Dotarem ® , Patient unable give inform consent , Adult Trust , Pregnant lactate Patient unable undergo medical geographical , social psychological .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>cardiac MRI</keyword>
	<keyword>Cancer</keyword>
	<keyword>Breast</keyword>
	<keyword>Herceptin</keyword>
	<keyword>LV dysfunction</keyword>
</DOC>